[Correspondence] Use of olaparib in patients with advanced gastric cancer

We read with great interest the results from the GOLD study,1 which compared olaparib plus paclitaxel with placebo plus paclitaxel as second-line therapy for patients with advanced gastric cancer in a double-blind, randomised phase 3 setting. Despite the negative result, some aspects of the study warrant closer attention in comparison with the previous phase 2 trial (Study 39; NCT01063517), which showed a positive finding.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Correspondence Source Type: research